PRKCI, protein kinase C iota, 5584

N. diseases: 78; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE Previous in-vitro studies have shown that 5-amino-1-((1R,2S,3S,4R)-2,3-dihydroxy-4-methylcyclopentyl)-1H-imidazole-4-carboxamide (ICA-1s), a PKC-ι specific inhibitor, is effective against some cancer cell lines by decreasing cell growth and inducing apoptosis. 30204596 2019
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 AlteredExpression group BEFREE Of these, PRKCI is one of the most frequently amplified and overexpressed genes and its expression induced cancer cell proliferation and migration/invasion <i>in vitro</i> as well as tumor growth <i>in vivo</i>. 29228547 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 AlteredExpression group BEFREE Protein kinase C iota (PKCι), a serine/threonine kinase required for cell polarity, proliferation and migration, is commonly up- or downregulated in cancer. 24072773 2014
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.040 Biomarker group BEFREE This function appears to be restricted to cancer cells and inhibition of PKCι may therefore be an effective way to selectively activate premature senescence in cancer cells. 22120720 2012